Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/66632
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abrego Escobar, Guadalupe | - |
dc.contributor.author | Alvarado, Helen | - |
dc.contributor.author | Souto, Eliana B. | - |
dc.contributor.author | Guevara, Bessy | - |
dc.contributor.author | Halbaut, Lyda | - |
dc.contributor.author | Parra Coca, Alexander | - |
dc.contributor.author | Calpena Campmany, Ana Cristina | - |
dc.contributor.author | García López, María Luisa | - |
dc.date.accessioned | 2015-07-29T08:44:46Z | - |
dc.date.available | 2016-02-11T23:01:52Z | - |
dc.date.issued | 2015-02-11 | - |
dc.identifier.issn | 0939-6411 | - |
dc.identifier.uri | http://hdl.handle.net/2445/66632 | - |
dc.description.abstract | Two optimized pranoprofen-loaded poly-L-lactic-co glycolic acid (PLGA) nanoparticles (PF-F1NPs; PF- 39 F2NPs) have been developed and further dispersed into hydrogels for the production of semi-solid formu- 40 lations intended for ocular administration. The optimized PF-NP suspensions were dispersed in freshly 41 prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone 42 (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical profile 43 of the selected non-steroidal anti-inflammatory drug (NSAID), by prolonging the contact of the pranopro- 44 fen with the eye, increasing the drug retention in the organ and enhancing its anti-inflammatory and 45 analgesic efficiency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations 46 with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for 47 ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sus- 48 tained release behavior. The results obtained from ex vivo corneal permeation and in vivo anti-inflamma- 49 tory efficacy studies suggest that the ocular application of the hydrogels containing azone was more 50 effective over the azone-free formulations in the treatment of edema on the ocular surface. No signs of 51 ocular irritancy have been detected for the produced hydrogels. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isformatof | Versió postprint del document publicat a: http://dx.doi.org/10.1016/j.ejpb.2015.01.026 | - |
dc.relation.ispartof | European Journal of Pharmaceutics and Biopharmaceutics, 2015 | - |
dc.relation.uri | http://dx.doi.org/10.1016/j.ejpb.2015.01.026 | - |
dc.rights | cc-by-nc-nd (c) Elsevier B.V., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Antiinflamatoris no esteroïdals | - |
dc.subject.classification | Nanopartícules | - |
dc.subject.classification | Terapèutica oftalmològica | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.other | Nonsteroidal anti-inflammatory agents | - |
dc.subject.other | Nanoparticles | - |
dc.subject.other | Ophthalmological therapeutics | - |
dc.subject.other | Administration of drugs | - |
dc.title | Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 647946 | - |
dc.date.updated | 2015-07-29T08:44:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25681744 | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
647946.pdf | 1.22 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License